慢性阻塞性肺疾病三联用药定量吸入剂的研究现状
发布时间：2018-07-31 20:29
【摘要】：慢性阻塞性肺疾病(COPD)是常见的慢性呼吸系统疾病,患病率高,疾病负担重,且无法完全治愈。吸入激素/长效β受体激动药/长效抗胆碱能药(ICS/LABA/LAMA)三药联合治疗相比于ICS/LABA或LAMA单药治疗,可改善患者的肺功能、症状和健康状况,减少急性加重的发生。三联治疗可提高用药依从性和疗效,但不易调整单一组份的剂量。本文旨在为今后临床合理应用该类型吸入剂提供参考。
[Abstract]:Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease. The combination therapy of inhaled hormone / long-acting 尾 receptor activator / long-acting anticholinergic (ICS/LABA/LAMA) can improve the pulmonary function, symptoms and health status of patients compared with ICS/LABA or LAMA monotherapy, and reduce the occurrence of acute exacerbation. Triple therapy can improve drug compliance and efficacy, but it is not easy to adjust the dose of a single component. The purpose of this article is to provide reference for the rational application of this type of inhalant in clinical practice in the future.
【作者单位】： 北京大学第一医院药剂科;
【分类号】：R563.9
本文编号：2156744
[Abstract]:Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease. The combination therapy of inhaled hormone / long-acting 尾 receptor activator / long-acting anticholinergic (ICS/LABA/LAMA) can improve the pulmonary function, symptoms and health status of patients compared with ICS/LABA or LAMA monotherapy, and reduce the occurrence of acute exacerbation. Triple therapy can improve drug compliance and efficacy, but it is not easy to adjust the dose of a single component. The purpose of this article is to provide reference for the rational application of this type of inhalant in clinical practice in the future.
【作者单位】： 北京大学第一医院药剂科;
【分类号】：R563.9
【相似文献】
相关期刊论文 前5条
1 吴荷馨;;冬病夏治三联疗法防治慢性阻塞性肺部疾病稳定期疗效观察[J];中医药临床杂志;2011年10期
2 刘远明;黎秀兰;;自拟定喘汤合三联疗法治疗慢性阻塞性肺疾病急性加重期的临床观察[J];中国卫生产业;2011年36期
3 王洪武;慢性阻塞性肺疾病研究新进展[J];海军总医院学报;2003年02期
4 张扬;陈建荣;;长效抗胆碱能药在治疗COPD中的应用[J];中国微循环;2006年03期
5 ;吸入ICS/LABA复合制剂可增加COPD患者肺炎风险[J];中国医学创新;2014年21期
，本文编号：2156744
本文链接：https://www.wllwen.com/yixuelunwen/huxijib/2156744.html
最近更新
教材专著
